A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

OBJECTIVE: To determine the degree to which alpha-glucosidase inhibitors, with their unique mode of action primarily reducing postprandial hyperglycemia, offer an additional therapeutic approach in the long-term treatment of type 2 diabetes. RESEARCH DESIGN AND METHODS: We studied 1,946 patients (63...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Holman, R, Cull, C, Turner, R
Formato:	Journal article
Idioma:	English
Publicado em:	1999

Registros relacionados

Glycaemic improvement over one year in a double-blind trial of acarbose in 1,946 NIDDM patients
por: Holman, R, et al.
Publicado em: (1996)

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
por: Davis, T, et al.
Publicado em: (2001)

Acarbose was effective in maintaining glycemic control in type 2 diabetes mellitus but was associated with adverse effects
por: Holman, R, et al.
Publicado em: (1999)

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
por: Retnakaran, R, et al.
Publicado em: (2006)

UK prospective diabetes study
por: Turner, R, et al.
Publicado em: (1996)

Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.
por: Colagiuri, S, et al.
Publicado em: (2002)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
por: Turner, R, et al.
Publicado em: (1999)

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
por: Wright, A, et al.
Publicado em: (2002)

Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters
por: P. Rosenbaum, et al.
Publicado em: (2002-08-01)

The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results
por: Levy, J, et al.
Publicado em: (1993)

[The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results]
por: Levy, J, et al.
Publicado em: (1993)

Possible prevention of type 2 diabetes with acarbose or metformin over three years
por: Citroen, H, et al.
Publicado em: (2000)

Two weeks of acarbose treatment shows no effect on gut microbiome composition in patients with type 2 diabetes: a randomised, placebocontrolled, double-blind, crossover study
por: Niels B Dalsgaard, et al.
Publicado em: (2024-07-01)

The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group.
por: Turner, R, et al.
Publicado em: (1996)

U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM.
por: Davis, T, et al.
Publicado em: (1997)

The UK Prospective Diabetes Study
por: Turner, R, et al.
Publicado em: (1996)

Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study.
por: Thomason, M, et al.
Publicado em: (2005)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)
por: Turner, R, et al.
Publicado em: (1999)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
por: Matthews, DR, et al.
Publicado em: (1998)

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
por: Holman, R, et al.
Publicado em: (2017)

Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32).
por: Adler, A, et al.
Publicado em: (1998)

U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease
por: Holman, R, et al.
Publicado em: (1995)

Lessons from UK prospective diabetes study.
por: Turner, R, et al.
Publicado em: (1995)

UK PROSPECTIVE DIABETES STUDY (UKPDS) .10. URINARY ALBUMIN EXCRETION OVER 3 YEARS IN DIET-TREATED TYPE-2, (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS, AND ASSOCIATION WITH HYPERTENSION, HYPERGLYCEMIA AND HYPERTRIGLYCERIDEMIA
por: Cull, C, et al.
Publicado em: (1993)

The UK Prospective Diabetes Study - Reply
por: Turner, R, et al.
Publicado em: (1998)

Butyrylcholinesterase K variant on chromosome 3q is associated with Type II diabetes in white Caucasian subjects (vol 44, pg 2227, 2001)
por: Hashim, Y, et al.
Publicado em: (2002)

Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients
por: He K, et al.
Publicado em: (2014-06-01)

A randomized controlled trial comparing acarbose vs. insulin therapy for gestational diabetes in individuals with inadequate glycemic control by diet alone
por: J. A. Villarreal-Rodriguez, et al.
Publicado em: (2020-08-01)

Erratum: Butyrylcholinesterase K variant on chromosome 3q is associated with Type II diabetes in white Caucasian subjects (Diabetologia (2001) 44 (2227-2230))
por: Hashim, Y, et al.
Publicado em: (2002)

UK PROSPECTIVE DIABETES STUDY 16 - OVERVIEW OF 6 YEARS THERAPY OF TYPE-II DIABETES - A PROGRESSIVE DISEASE
por: Turner, R, et al.
Publicado em: (1995)

UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.
por: Turner, R, et al.
Publicado em: (1991)

Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
por: Elizabeth Philip, et al.
Publicado em: (2013-01-01)

Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
por: Hae Kyung Yang, et al.
Publicado em: (2019-06-01)

UKPDS: what was the question? UK Prospective Diabetes Study.
por: Turner, R, et al.
Publicado em: (1999)

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
por: Rosak C, et al.
Publicado em: (2012-10-01)

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.
por: Turner, R, et al.
Publicado em: (1996)

United Kingdom prospective diabetes study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus
por: Turner, R, et al.
Publicado em: (1996)

UK prospective diabetes study
por: Holman, R
Publicado em: (1990)

The effect of Silymarin on glycemic control of type II diabetes: A double blind randomized clinical trial
por: H Fallah Huseini, et al.
Publicado em: (2005-02-01)

PROGRESSION OF DIABETIC-RETINOPATHY IN TYPE-2 DIABETIC-PATIENTS IN THE UK PROSPECTIVE DIABETES STUDY
por: Stratton, I, et al.
Publicado em: (1993)